将大数据纳入治疗计划评估:统计DVH指标与可视化仪表盘的开发
本研究开发了基于统计剂量体积直方图(DVH)的指标及可视化方法,用于将治疗计划与历史经验及不同机构间进行量化比较。通过分析头颈癌、前列腺癌和肝癌患者的历史计划,构建了加权经验评分(WES)和广义评估指标(GEM),并开发了可共享的仪表盘插件集成于治疗计划系统中。结果表明统计DVH能直观展示量化比较,WES和GEM可将离散阈值优先级与历史背景整合为标准化评分指标。
要点
- 统计DVH图可直观展示计划与历史经验的量化比较。
- WES和GEM指标将离散阈值优先级和历史背景转化为连续评分。
- 仪表盘插件可在治疗计划系统内集成GEM和WES评分。
核心结论
- 统计DVH提供了一种易读、详细且全面的可视化方式,用于与历史经验及机构间进行定量比较。
- WES和GEM指标提供了一种灵活的方法,将离散阈值优先级和历史背景纳入标准化评分指标。
- 两者共同为将大数据纳入治疗计划评估的临床实践提供了实用方法。
研究设计与样本
- 开发性研究方法,对过去经验的体积归一化DVH曲线集进行描述性统计汇总并可视化。
- 分析了351例头颈癌、104例常规分割前列腺癌和94例立体定向体部放疗肝癌患者的历史治疗计划。
- 创建了可共享的仪表盘插件,用于在治疗计划系统内显示统计DVH并整合GEM和WES评分。
- 使用正常组织并发症概率评分进行基准测试,以比较GEM和WES评分的行为。
主要发现
- 对历史治疗计划的DVH曲线进行了表征和呈现,并识别了难以保护的结构(即经常受损的危及器官)。
- GEM和/或WES的定量评估与正常组织并发症概率Lyman-Kutcher-Burman模型相比表现良好。
- 将一组离散的阈值优先级限制转化为反映医生目标和历史经验的连续模型。
临床怎么用
- 在治疗计划评估中,可使用统计DVH图将当前计划与历史经验进行定量比较。
- 可利用WES和GEM指标将离散阈值优先级和历史背景整合为标准化评分。
- 可通过仪表盘插件在治疗计划系统内集成GEM和WES评分进行临床计划评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop statistical dose-volume histogram (DVH)-based metrics and a visualization method to quantify the comparison of treatment plans with historical experience and among different institutions. METHODS AND MATERIALS: The descriptive statistical summary (ie, median, first and third quartiles, and 95% confidence intervals) of volume-normalized DVH curve sets of past experiences was visualized through the creation of statistical DVH plots. Detailed distribution parameters were calculated and stored in JavaScript Object Notation files to facilitate management, including transfer and potential multi-institutional comparisons. In the treatment plan evaluation, structure DVH curves were scored against computed statistical DVHs and weighted experience scores (WESs). Individual, clinically used, DVH-based metrics were integrated into a generalized evaluation metric (GEM) as a priority-weighted sum of normalized incomplete gamma functions. Historical treatment plans for 351 patients with head and neck cancer, 104 with prostate cancer who were treated with conventional fractionation, and 94 with liver cancer who were treated with stereotactic body radiation therapy were analyzed to demonstrate the usage of statistical DVH, WES, and GEM in a plan evaluation. A shareable dashboard plugin was created to display statistical DVHs and integrate GEM and WES scores into a clinical plan evaluation within the treatment planning system. Benchmarking with normal tissue complication probability scores was carried out to compare the behavior of GEM and WES scores. RESULTS: DVH curves from historical treatment plans were characterized and presented, with difficult-to-spare structures (ie, frequently compromised organs at risk) identified. Quantitative evaluations by GEM and/or WES compared favorably with the normal tissue complication probability Lyman-Kutcher-Burman model, transforming a set of discrete threshold-priority limits into a continuous model reflecting physician objectives and historical experience. CONCLUSIONS: Statistical DVH offers an easy-to-read, detailed, and comprehensive way to visualize the quantitative comparison with historical experiences and among institutions. WES and GEM metrics offer a flexible means of incorporating discrete threshold-prioritizations and historic context into a set of standardized scoring metrics. Together, they provide a practical approach for incorporating big data into clinical practice for treatment plan evaluations.
引用
- Mayo CS, Yao J, Eisbruch A, et al. Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards. Adv Radiat Oncol. 2017. PMID: 29114619. doi:10.1016/j.adro.2017.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。